Covid-19 roundup: Regeneron's mAB gets expanded EUA; mRNA drugmakers spike price of vaccines in EU supply deal
The FDA has expanded the authorization for Regeneron’s Covid-19 treatment Regen-Cov in an announcement Friday.
The authorization now covers post-exposure prophylaxis for those exposed to an infected person or who are at high risk of exposure “in an institutional setting” like a nursing home or a prison, and are not fully vaccinated or expected to provide a sufficient immune response.
Regeneron experts predict that 3% of the US population may not be able to fully respond to Covid-19 vaccinations.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.